Cortexyme, Inc., a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, has announced the.
The oral bacteria Porphyromonas gingivalis invades neurons and triggers Alzheimer’s-like neuropathology, according to research funded by the clinical stage biopharmaceutical company Cortexyme.
Porphyromonas gingivalis can travel throughout the body and exude toxins connected with Alzheimer’s disease, rheumatoid arthritis, and aspiration pneumonia, report researchers at the.
Porphyromonas gingivalis (Pg) plays a role in driving Alzheimer’s disease (AD) pathology, according to researchers at Cortexyme. But the privately held, clinical-stage pharmaceutical.
